Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

(2023) Gideon M. Hirschfield et al.   HEPATOLOGY

Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway

(2022) Tetsuya Kouno et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

(2022) Christopher L. Bowlus et al.   JOURNAL OF HEPATOLOGY

UK-Wide Multicentre Evaluation of Second Line Therapies in Primary Biliary Cholangitis

(2022) Nadir Abbas et al.   Clinical Gastroenterology and Hepatology

Liver transplant‐free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid

(2022) Rozanne C. de Veer et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Recent advances in clinical practice: epidemiology of autoimmune liver diseases

(2021) Palak J Trivedi et al.   GUT

Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis

(2021) Andreas E. Kremer et al.   LIVER INTERNATIONAL

Goals of Treatment for Improved Survival in Primary Biliary Cholangitis

(2020) Carla F. Murillo Perez et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Emerging therapies for PBC

(2020) David Maxwell Hunter Chascsa et al.   JOURNAL OF GASTROENTEROLOGY

Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis

(2020) Alessio Gerussi et al.   Clinical Gastroenterology and Hepatology

Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study

(2019) Michael Trauner et al.   Lancet Gastroenterology & Hepatology

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis

(2018) Kris V. Kowdley et al.   HEPATOLOGY

PBC-transplantation and disease recurrence

(2018) Frederik Nevens   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases

(2018) Keith D. Lindor et al.   HEPATOLOGY

Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades

(2018) Maren H. Harms et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis

(2017) Gideon M. Hirschfield et al.   JOURNAL OF HEPATOLOGY

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

(2016) Frederik Nevens et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes

(2015) A. C. Cheung et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid

(2015) Gideon M. Hirschfield et al.   GASTROENTEROLOGY

Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy

(2015) Willem J. Lammers et al.   GASTROENTEROLOGY

The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis

(2015) Marco Carbone et al.   HEPATOLOGY

The immunogenetics of primary biliary cirrhosis: A comprehensive review

(2015) G.J. Webb et al.   JOURNAL OF AUTOIMMUNITY

Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study

(2014) Willem J. Lammers et al.   GASTROENTEROLOGY

Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: Results of a 14-year cohort study

(2013) Li-Na Zhang et al.   HEPATOLOGY

Sex and Age Are Determinants of the Clinical Phenotype of Primary Biliary Cirrhosis and Response to Ursodeoxycholic Acid

(2012) Marco Carbone et al.   GASTROENTEROLOGY

Protection from liver fibrosis by a peroxisome proliferator-activated receptor   agonist

(2012) K. Iwaisako et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia

(2011) Yun-Jung Choi et al.   ATHEROSCLEROSIS

MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin

(2011) Harold E. Bays et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid

(2010) C. Levy et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis

(2010) Teru Kumagi et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Improved Prognosis of Patients With Primary Biliary Cirrhosis That Have a Biochemical Response to Ursodeoxycholic Acid

(2009) Edith M.M. Kuiper et al.   GASTROENTEROLOGY

Peroxisome proliferator-activated receptor delta activation leads to increased transintestinal cholesterol efflux

(2009) Carlos L. J. Vrins et al.   JOURNAL OF LIPID RESEARCH